ONECUT2 and breast cancer: Treatment with a small molecule inhibitor of OC2, compound CSRM617 [15], inhibited cell growth in several BC cell lines, including the highly aggressive mouse 4T1 triple-negative tumor model that expresses relatively high OC2 levels (Fig. 5C, D and Supplementary Fig. 5B), phenocopying the effects observed when OC2 was depleted with shRNA or siRNA (Fig. 5A, B).